Leading Mid-Corporates of India 2022

16 Experts' View Leading Mid-Corporates of India 2022 How would you describe the journey of your company since its inception? What are some of the key milestones of the company in recent years? RPG Life Sciences is an over five- decades-old pharma company – that started as a joint venture with GD Searle, USA. With Searle exiting India, the company got rechristened as RPG Life Sciences, inheriting iconic/text- book brands, R&D/Manufacturing/ Regulatory infrastructure, processes, and equity. It is amongst the few mid-size pharma companies - well- represented in all three segments viz. Domestic Formulations, International Formulations, and APIs having the manufacturing infrastructure, organization-structure, experience, and skill-set of an evolved organization with strong front-end and back-end capabilities. Backed by a well-conceptualized Transformation-agenda devised and being diligently executed by a ~1200-strong team for the last 3 years, we have emerged today as a benchmark mid-size company with revenue growth significantly-and- consistently-higher-than-the-market, all 3 segments growing healthy RPG Life Sciences Limited Yugal Sikri Managing Director double-digit, profitability and profits grown manifold, become debt- free - generating healthy positive cashflows, reached either the top or amongst top 3 comparator companies in key financial ratios - all eventually reflecting in our market cap leapfrogging ~ 5-6X, significantly ahead of BSE Healthcare index growth. What are some of the innovative initiatives taken by your company in recent years? Innovation and digitalization form the cornerstone of our transformation agenda. A slew of initiatives across the front-end and back-end have been launched. One such initiative is RPGServ, a unique digital platform for comprehensivedoctors’ engagement that integrates physical and digital capabilities (Phygital) to provide an Industry-first “Anytime, Anywhere Doctor Support Initiative” multiplying our customer access and SoV. RPG is perhaps the only corporate globally which has adopted “Happiness” as its theme. We have devised a comprehensive Happiness framework, formed a Happiness council, launched a host of well- crafted initiatives, included them in Managers’ KRAs, and measure them diligently. What is your outlook on the Pharma & Healthcare sector? What is your company’s growth strategy for next 3-5 years? India pharma is a structural growth story being driven by wide- ranging demographic, economic, geographic, and infra-structural factors that are likely to sustain over years. The overall strategy of the company is to have a pie of India opportunity. We aim to have consistent profitable business growth, leveraging all three business segments with top priority to Domestic Formulations that contributes to two-thirds of the overall business. The strategy for Domestic Formulations is built around five pillars, namely: • Product Portfolio Rejuvenation by building chronic and specialty portfolios with new launches • Strategic Brand Asset Building through Life cycle management by launching new line extensions • DeepeningCustomerCoverage in targeted therapies by expanding field force and deploying digital • Augmenting Salesforce Effectiveness by competencies building and productivity enhancement initiatives • Improving Profitability by Opex control, product re-engineering, efficient manufacturing operations, and ensuring business hygiene The strategy for our international business - both API and Formulations, is step-wise profitable business build- up via carefully curated pillars and a well-defined roadmap • Augment and expand our strong niche - immunosuppressant portfolio • Build product-pipeline with a specific competitive advantage and low competitive intensity • Expand footprints in both emerging and regulated markets • Grow existing products through New Line Extensions-New Customers-New Markets • Invest in building state-of- art Manufacturing/R&D infra- structure All of the above is being built on a strong foundation of a well-defined company’s purpose, corporate governance architecture, ESG framework with an over-arching goal to be a benchmark company. Dun & Bradstreet